COLORADO SPRINGS, Colo.–(BUSINESS WIRE)– Cannabis Science, Inc. (OTCBB: CBIS.OB – News), a pioneering US biotech company developing pharmaceutical cannabis products, is happy to report an additional, apparently successful, self-medicated cannabis treatment for a cancer patient. This case is very graphic in nature. One of the patient’s physicians said it was the worst case of squamous cell carcinoma cancer he had ever seen, while another refused to continue tending to the patient.
Please go to our website www.cannabisscience.com to click our new button “Breaking News, Successful Cancer Treatment Case Studies” section that now includes graphic images of this Cancer Patient’s Graphic Progress Pictures.
The first picture shows a large tumor protruding a few inches above the surface of the patient’s skull prior to treatment. The cannabis-based extract was applied into the holes and the surrounding tissue that are seen in this patient’s scalp that extended down to the skull.
The second photograph shows the patient’s head after receiving one of many radiation treatments. Subsequent photos demonstrate what appears to be the cannabis extract drawing out, and killing the cancer cells from these lesions.
While this patient’s self-administered treatment with cannabis extracts is still in progress, the results after just two weeks of treatment are dramatic. Some of the tumors have disappeared and others have significantly shrunk to a fraction of their original size. Simultaneously, the patient has had a significant decrease in pain, improved sleeping (the 1st full night of sleep in 3 years), as well as relief from the symptoms of multiple sclerosis that the patient also suffers from. This self-treatment is a work in progress.
Cannabis Science is showing the general public unbiased evidence as we acquire it independent of the final outcome. As the treatment continues, and physician determinations are made, we will continue to update you so that you can follow the effectiveness of this treatment as it progresses.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
Investor Relations Management